国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2014年
7期
1253-1256
,共4页
姜虎林%韩旭巍%张生奇%房修岭%赵博军
薑虎林%韓旭巍%張生奇%房脩嶺%趙博軍
강호림%한욱외%장생기%방수령%조박군
雷珠单抗%格栅样光凝%糖尿病黄斑水肿
雷珠單抗%格柵樣光凝%糖尿病黃斑水腫
뢰주단항%격책양광응%당뇨병황반수종
ranibizumab%grid photocoagulation%diabetic macular edema
目的：评价玻璃体腔内注射雷珠单抗( ranibizumab )联合黄斑格栅样光凝治疗糖尿病黄斑水肿的临床价值。<br> 方法：确诊为糖尿病黄斑水肿的患者60例60眼按照随机原则分为两组：单纯注药组30例30眼,行玻璃体腔内雷珠单抗注射；联合治疗组30例30眼,先行玻璃体腔内雷珠单抗注射,再于注药1 wk后行黄斑格栅样光凝。观察两组治疗后最佳矫正视力( BCVA ),光学相干断层扫描( OCT )显示的黄斑中心凹厚度( CMT )及术后并发症等。<br> 结果：单纯注药组治疗后4,8,12 wk 的 BCVA 分别为0.390±0.075,0.367±0.088,0.319±0.064,CMT分别为221.63±112.34,337.73±99.56,432.92±100.46μm,与治疗前相比效果明显,但治疗后随访期间BCVA呈现下降趋势,CMT呈现上升趋势。而联合治疗组治疗后4,8,12wk的BCVA分别为0.385±0.036,0.382±0.079,0.377±0.097,CMT分别为249.77±106.55,270.40±92.88,275.84±97.34μm,可见治疗后效果满意,且随访期间疗效保持平稳。治疗后8,12 wk联合治疗组BCVA及CMT均优于单纯治疗组(P<0.05)。<br> 结论：玻璃体腔内注射雷珠单抗能够有效提高糖尿病黄斑水肿患者的视力,降低黄斑中心凹厚度,联合黄斑格栅样光凝治疗更能保证疗效稳定而持久。
目的：評價玻璃體腔內註射雷珠單抗( ranibizumab )聯閤黃斑格柵樣光凝治療糖尿病黃斑水腫的臨床價值。<br> 方法：確診為糖尿病黃斑水腫的患者60例60眼按照隨機原則分為兩組：單純註藥組30例30眼,行玻璃體腔內雷珠單抗註射；聯閤治療組30例30眼,先行玻璃體腔內雷珠單抗註射,再于註藥1 wk後行黃斑格柵樣光凝。觀察兩組治療後最佳矯正視力( BCVA ),光學相榦斷層掃描( OCT )顯示的黃斑中心凹厚度( CMT )及術後併髮癥等。<br> 結果：單純註藥組治療後4,8,12 wk 的 BCVA 分彆為0.390±0.075,0.367±0.088,0.319±0.064,CMT分彆為221.63±112.34,337.73±99.56,432.92±100.46μm,與治療前相比效果明顯,但治療後隨訪期間BCVA呈現下降趨勢,CMT呈現上升趨勢。而聯閤治療組治療後4,8,12wk的BCVA分彆為0.385±0.036,0.382±0.079,0.377±0.097,CMT分彆為249.77±106.55,270.40±92.88,275.84±97.34μm,可見治療後效果滿意,且隨訪期間療效保持平穩。治療後8,12 wk聯閤治療組BCVA及CMT均優于單純治療組(P<0.05)。<br> 結論：玻璃體腔內註射雷珠單抗能夠有效提高糖尿病黃斑水腫患者的視力,降低黃斑中心凹厚度,聯閤黃斑格柵樣光凝治療更能保證療效穩定而持久。
목적：평개파리체강내주사뢰주단항( ranibizumab )연합황반격책양광응치료당뇨병황반수종적림상개치。<br> 방법：학진위당뇨병황반수종적환자60례60안안조수궤원칙분위량조：단순주약조30례30안,행파리체강내뢰주단항주사；연합치료조30례30안,선행파리체강내뢰주단항주사,재우주약1 wk후행황반격책양광응。관찰량조치료후최가교정시력( BCVA ),광학상간단층소묘( OCT )현시적황반중심요후도( CMT )급술후병발증등。<br> 결과：단순주약조치료후4,8,12 wk 적 BCVA 분별위0.390±0.075,0.367±0.088,0.319±0.064,CMT분별위221.63±112.34,337.73±99.56,432.92±100.46μm,여치료전상비효과명현,단치료후수방기간BCVA정현하강추세,CMT정현상승추세。이연합치료조치료후4,8,12wk적BCVA분별위0.385±0.036,0.382±0.079,0.377±0.097,CMT분별위249.77±106.55,270.40±92.88,275.84±97.34μm,가견치료후효과만의,차수방기간료효보지평은。치료후8,12 wk연합치료조BCVA급CMT균우우단순치료조(P<0.05)。<br> 결론：파리체강내주사뢰주단항능구유효제고당뇨병황반수종환자적시력,강저황반중심요후도,연합황반격책양광응치료경능보증료효은정이지구。
AlM:To evaluate the clinical efficacy of intravitreal injection of ranibizumab combined with macular grid photocoagulation for diabetic macular edema ( DME) .METHODS:Totally 60 eyes ( 60 patients ) with DME were randomly divided into 2 groups: 30 eyes of simple injection group underwent intravitreal injection of ranibizumab, and 30 eyes of combined treatment group underwent intravitreal injection of ranibizumab and macular grid photocoagulation 1wk later. The best corrected visual acuity ( BCVA ) , central macular thickness ( CMT ) measured by optical coherence tomography ( OCT ) and postoperative complications were observed. <br> RESULTS:ln simple injection group, the BCVA after operation were separately 0. 390 ± 0. 075 (4wk), 0. 367 ± 0. 088 (8wk) and 0. 319 ± 0. 064 (12wk), the CMT after operation were separately 221. 63 ± 112. 34μm (4wk), 337. 73±99. 56μm (8wk) and 432. 92 ± 100. 46μm (12wk), which were much better than pre-operation. But during follow-up, the BCVA presented down trend and the CMT was on the rise slowly. ln combined treatment group, the BCVA after operation were separately 0. 385 ± 0. 036 (4wk), 0.382±0.079 (8wk) and 0.377±0.097 (12wk),the CMT after operation were separately 249. 77 ± 106. 55μm (4wk), 270. 40 ± 92. 88μm (8wk) and 275. 84 ± 97. 34μm (12wk ), which were satisfactory and steady during follow-up, better than simple injection group (P<0. 05).CONCLUSlON:lntravitreal injection of ranibizumab can effectively improve visual acuity and decrease central foveal thickness for patients with DME, combining with macular grid photocoagulation can ensure therapeutic effects steady and permanent.
